**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% шанс
$131,745 Обс.
$131,745 Обс.
Dec 31, 2026
6% шанс
$131,745 Обс.
$131,745 Обс.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Ринок відкрито: May 4, 2026, 10:39 AM ET
Обсяг
$131,745Дата завершення
Jan 1, 2027Ринок відкрито
May 4, 2026, 10:39 AM ETВирішувач
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Обсяг
$131,745Дата завершення
Jan 1, 2027Ринок відкрито
May 4, 2026, 10:39 AM ETВирішувач
0x65070BE91...**No hantavirus vaccine is positioned for regulatory approval or widespread availability by the end of 2026, aligning with the market’s 94.5% implied probability on “No.”** Multiple candidates, including Moderna’s mRNA platform with Korea University and UTMB’s single-dose Andes-focused mRNA constructs, remain in preclinical or early Phase 1 stages as of mid-2026, with only animal protection data available and no completed large-scale human efficacy trials. Existing inactivated vaccines are limited to specific strains in China and South Korea and lack approval in the US or EU. Recent outbreaks, such as the Andes strain on the MV Hondius cruise ship, have heightened attention but have not accelerated any candidate past early development or secured emergency-use pathways. Standard vaccine timelines—often 8–15 years from preclinical work to licensure—plus challenges in conducting Phase 3 trials for a rare disease with dispersed cases reinforce the current trader consensus, though an unexpected surge in funding or breakthrough regulatory designation could theoretically shift timelines.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання